Conference on immune suppression in cancer

描述(申请人提供)：本次国际生物医学会议将于2007年1月25-28日在佛罗里达州克利尔沃特市的喜来登沙基酒店举行。这次会议的目的是促进肿瘤免疫学的最新发现和想法的交流。尽管前景看好，但癌症免疫疗法到目前为止还没有带来切实的临床好处。现在很明显，如果不了解肿瘤诱导免疫抑制的机制，这一领域的进一步进展是不可能的。到目前为止，已经提出了大量可能的癌症免疫抑制机制。它们为当前和未来的临床试验奠定了基础。然而，这些丰富的信息创造了一幅非常错综复杂的图景。提议的机制相互竞争。迫切需要整个领域讨论已经描述的和新出现的机制，看看如何以或多或少的协调一致的结构将它们放在一起。这将是第一次完全聚焦于肿瘤诱导的免疫抑制问题的会议。作为参与此教育计划的结果，参与者将能够： 评估癌症免疫治疗领域的最新进展； 回顾当前免疫治疗方案的成功和失败； 评价肿瘤诱导免疫抑制的不同机制； 讨论这些机制对癌症治疗失败的贡献； 研究不同的分子途径如何有助于肿瘤逃避免疫系统的控制； 回顾和讨论我们关于肿瘤相关免疫抑制新机制的知识如何转化为新的治疗方法

DESCRIPTION (provided by applicant): This international biomedical conference will be held January 25-28 2007 at Sheraton Sand Key Hotel in Clearwater, Florida. The purpose of this meeting is to foster exchange of the most recent findings and ideas in tumor immunology. Despite high promise, cancer immunotherapy so far has not delivered tangible clinical benefits. It is now clear that without understanding the mechanisms of tumor induced immune suppression, further progress in this area will not be possible. By this time a large number of possible mechanisms of immune suppression in cancer have been proposed. They form a foundation for current and future clinical trials. However, this wealth of information has created a very convoluted picture. Proposed mechanisms compete with each other. There is a pressing need for the entire field to discuss already described and new emerging mechanisms to see how they can be put together in more or less cohesive structure. This will be first conference entirely focused on the problem of tumor-induced immune suppression. As a result of participating in this educational program, participants will be able to: Assess recent progress in the filed of cancer immunotherapy; Review successes and failures of current immunotherapy regiments; Evaluate different mechanisms of tumor induced immune suppression; Discuss contribution of these mechanisms to failure of cancer treatment; Examine how different molecular pathways contribute to tumor escape of immune system control; Review and discuss how our knowledge of new mechanisms of tumor associated immune suppression can be translated into new therapeutics